Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Reports of the development and validation of the models were presented at ENDO 2025, the annual meeting of the Endocrine Society (Abstract OR24-08).
In an update from the UK phase III FLAIR trial reported in The New England Journal of Medicine, Munir et al compared the survival benefit of measurable residual disease (MRD)–guided therapy with ibrutinib/venetoclax vs ibrutinib alone in chronic lymphocytic leukemia.
Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few direct comparisons between the percutaneous approach and bronchoscopy, endobronchial ultrasound (EBUS), or mediastinoscopy regarding diagnostic accuracy, and it remains unknown which sampling technique is the safest and offers the most adequate material for comprehensive biomarker testing.
In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy (ADT).
Teclistamab-cqyv is the first bispecific T-cell engager antibody that targets both B-cell maturation antigen (BCMA) proteins on myeloma cells and CD3 proteins on T cells. It was approved by the U.S. Food and Drug Administration in 2022 for treatment of patients with relapsed or refractory multiple myeloma based on findings from the MajesTEC-1 trial.
Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...
New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...
W. Kimryn Rathmell, MD, PhD, FASCO W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role ...
Christian Rolfo, MD, PhD, MBA Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this...
In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings suggested the possibility of slightly increased risk with longer-term use. As noted by the...
In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...
Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...